The National Cancer Institute (NCI) seeks research co-development opportunities and/or licensees for a new biomedical device for biopsy tissue collection and storage in a sterile, well-defined environment.
Surgery specialists from Johns Hopkins University, in collaboration with researchers at the National Cancer Institute (NCI), developed peptide hydrogel compositions and methods to suture blood vessels during microsurgery. The hydrogels particularly benefit surgeons in whole tissue transplant procedures. The NCI seeks co-development research collaborations for further development of this technology.
Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.
The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method for target-activated microdissection.